Trandolapril/verapamil combination in hypertensive diabetic patients

José A García Donaire, Luis M RuilopeHypertension Unit, Hospital 12 de Octubre, Madrid, SpainAbstract: Cardiovascular diseases are directly affected by arterial hypertension. When associated with diabetes mellitus, the potential deleterious effects are well amplified. Both cond...

Full description

Bibliographic Details
Main Authors: José A García Donaire, Luis M Ruilope
Format: Article
Language:English
Published: Dove Medical Press 2007-03-01
Series:Vascular Health and Risk Management
Online Access:https://www.dovepress.com/trandolaprilverapamil-combination-in-hypertensive-diabetic-patients-peer-reviewed-article-VHRM
id doaj-55be307b284a4f42a76cb6e1241e3d6d
record_format Article
spelling doaj-55be307b284a4f42a76cb6e1241e3d6d2020-11-25T00:27:57ZengDove Medical PressVascular Health and Risk Management1178-20482007-03-01Volume 377821461Trandolapril/verapamil combination in hypertensive diabetic patientsJosé A García DonaireLuis M RuilopeJosé A García Donaire, Luis M RuilopeHypertension Unit, Hospital 12 de Octubre, Madrid, SpainAbstract: Cardiovascular diseases are directly affected by arterial hypertension. When associated with diabetes mellitus, the potential deleterious effects are well amplified. Both conditions play a central role in the pathogenesis of coronary artery disease, heart failure, stroke, and renal insufficiency. Prevalence of hypertension is much higher among diabetic than non-diabetic patients, and the hypertensive patient is more likely to develop type 2 diabetes. Current international guidelines recommend aggressive reductions in blood pressure (BP) in hypertensive patients with additional risk factors, including cardiovascular risk factors, and emphasize the relevance of intensive reduction in patients with diabetes mellitus; a goal of 130/80 mm Hg is required. To achieve BP target a combination of antihypertensives will be needed, and the use of long-acting drugs that are able to provide 24-hour efficacy with a once-daily dosing confers the noteworthy advantages of compliance improvement and BP variation lessening. Lower dosages of the individual treatments of the combination therapy can be administered for the same antihypertensive efficiency as that attained with high dosages of monotherapy. Angiotensin-converting enzyme inhibitors and calcium-channel blockers as a combination have theoretically compelling advantages for vessel homeostasis. Trandolapril/verapamil sustained release combination has showed beneficial effects on cardiac and renal systems as well as its antihypertensive efficacy, with no metabolic disturbances. This combination can be considered as an effective therapy for the diabetic hypertensive population.Keywords: hypertension, trandolapril, verapamil, diabetes, renin-angiotensin system, combination therapyhttps://www.dovepress.com/trandolaprilverapamil-combination-in-hypertensive-diabetic-patients-peer-reviewed-article-VHRM
collection DOAJ
language English
format Article
sources DOAJ
author José A García Donaire
Luis M Ruilope
spellingShingle José A García Donaire
Luis M Ruilope
Trandolapril/verapamil combination in hypertensive diabetic patients
Vascular Health and Risk Management
author_facet José A García Donaire
Luis M Ruilope
author_sort José A García Donaire
title Trandolapril/verapamil combination in hypertensive diabetic patients
title_short Trandolapril/verapamil combination in hypertensive diabetic patients
title_full Trandolapril/verapamil combination in hypertensive diabetic patients
title_fullStr Trandolapril/verapamil combination in hypertensive diabetic patients
title_full_unstemmed Trandolapril/verapamil combination in hypertensive diabetic patients
title_sort trandolapril/verapamil combination in hypertensive diabetic patients
publisher Dove Medical Press
series Vascular Health and Risk Management
issn 1178-2048
publishDate 2007-03-01
description José A García Donaire, Luis M RuilopeHypertension Unit, Hospital 12 de Octubre, Madrid, SpainAbstract: Cardiovascular diseases are directly affected by arterial hypertension. When associated with diabetes mellitus, the potential deleterious effects are well amplified. Both conditions play a central role in the pathogenesis of coronary artery disease, heart failure, stroke, and renal insufficiency. Prevalence of hypertension is much higher among diabetic than non-diabetic patients, and the hypertensive patient is more likely to develop type 2 diabetes. Current international guidelines recommend aggressive reductions in blood pressure (BP) in hypertensive patients with additional risk factors, including cardiovascular risk factors, and emphasize the relevance of intensive reduction in patients with diabetes mellitus; a goal of 130/80 mm Hg is required. To achieve BP target a combination of antihypertensives will be needed, and the use of long-acting drugs that are able to provide 24-hour efficacy with a once-daily dosing confers the noteworthy advantages of compliance improvement and BP variation lessening. Lower dosages of the individual treatments of the combination therapy can be administered for the same antihypertensive efficiency as that attained with high dosages of monotherapy. Angiotensin-converting enzyme inhibitors and calcium-channel blockers as a combination have theoretically compelling advantages for vessel homeostasis. Trandolapril/verapamil sustained release combination has showed beneficial effects on cardiac and renal systems as well as its antihypertensive efficacy, with no metabolic disturbances. This combination can be considered as an effective therapy for the diabetic hypertensive population.Keywords: hypertension, trandolapril, verapamil, diabetes, renin-angiotensin system, combination therapy
url https://www.dovepress.com/trandolaprilverapamil-combination-in-hypertensive-diabetic-patients-peer-reviewed-article-VHRM
work_keys_str_mv AT joseacuteagarciacuteadonaire trandolaprilverapamilcombinationinhypertensivediabeticpatients
AT luismruilope trandolaprilverapamilcombinationinhypertensivediabeticpatients
_version_ 1725337531822637056